12.10.18: Not intended for U.S. and UK Media

U.S. FDA approves Bayer's Xarelto® for patients with coronary or peripheral artery diseaseXarelto, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease / Xarelto, in combination with aspirin, is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated for this patient group / Approval in the U.S. follows regulatory clearance in both Europe and Canadamehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news